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The aim of this brief introductory review is to consider the approaches that have been taken
over the last half-century to the classification of the inflammatory myopathies (myositides).
Reclassification has been suggested periodically, mainly on the basis of developments in the
immunocytochemical analysis of muscle biopsy specimens, which we believe gives us new
insights into pathogenetic mechanisms, and observations on associated immune phenomena. I
will conclude that despite these apparent advances we are arguably little closer to a universally
agreed system of classification, but nonetheless will suggest a framework that is helpful for
everyday clinical practice.
Broadly speaking, myositis may be seen in one of three settings. Least commonly a specific cause
can be identified–examples include infections directly involving muscle, and drug- and toxin-
induced myositis (e.g. statins, macrophagic myofasciitis). Secondly, myositis may be seen in
association with additional specific clinic-pathological features or separately recognised disease
(e.g. hypereosinophilia, sarcoidosis, vasculitis). This group includes well-defined connective
tissue disorders (e.g. rheumatoid arthritis, SLE, Sjögren’s syndrome, scleroderma). The third
group, and the one that causes the greatest difficulties with classification, comprises the
idiopathic inflammatory myopathies (IIM)–by convention this is taken to include dermatomyo-
sitis (DM), polymyositis (PM) and sporadic inclusion-body myositis (sIBM). Whether sIBM should
be included is open to debate. As will be discussed, there is significant overlap between the
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Summary
This brief review considers historical approaches to the classification of the inflammatory
myopathies. The last 25 years have seen advances in our knowledge of the underlying immune
mechanism but the initial trigger for the idiopathic inflammatory myopathies remains
unknown. Existing classifications have their limitations, but with the absence of a ‘‘gold
standard’’ a definitive classification is not yet possible. Despite these problems, a working
classification is possible that is valuable for everyday clinical practice.
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D Hilton-Jonessecond and third groups; features of connective tissue disease,
both immunological and clinical, may be seen in association
with PM and DM. Furthermore, so-called ‘‘idiopathic’’ inflam-
matory myopathies may not always be idiopathic and DM at
least has a significant association with neoplasia.
There is currently a popular television quiz programme, fran-
chised around the world, called ‘‘Who wants to be a million-
aire?’’. If the contestant does not know, or is uncertain of, the
answer to a question he or she may ‘‘phone a friend’’. In a
similar idiom I emailed five friends, all of whom would in-
dubitably be considered world authorities in the field of myol-
ogy, and asked them for their definition of myositis, and their
approach to classification. It was encouraging, to me at least,
that our views were broadly very similar differing more in
nuance than degree. At a pathological level, myositis can be
defined simply as the presence of an inflammatory exudate.
However, the absence of such an appearance in a muscle
biopsy specimen cannot be taken to exclude the diagnosis of
an inflammatory myopathy–by chance a small biopsy may miss
the characteristic changes, which may be identified if the
biopsy is repeated from another site; this seems to be a
particularly common experience in DM. We also have to en-
compass the concept of autoimmune necrotizing myopathy–
muscle shows necrosis and regeneration, but a complete
absence of inflammatory cells. Expression of MHC-1 is consi-
dered a surrogate marker of inflammation and an immune
aetiology is supported by a clinical response to steroids and
immunosuppression. Perhaps considering these observations,
one correspondent said that he had abandoned using the word
myositis in favour of the term inflammatory myopathy. As well
as pathological features, the definition of myositis may be
taken to include reference to the presence and pattern of
muscle weakness, electromyographic changes, and elevation
of muscle enzymes.
We had little disagreement on the broad classification of the
myositides, except for the popular late-night debate amongstssary
connective-tissue disease
dermatomyositis
idiopathic inflammatory myopathies
interstitial lung disease
CS International Myositis Assessment and Clinical
Studies
D mixed connective tissue disease
myositis-specific antibodies
polymyositis
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signal recognition particlemyologists of whether there is such a condition as ‘‘pure PM’’,
an issue I will return to later. The oldest, and I would suggest
wisest, respondent noted his dislike of rigid definitions in that
they ‘‘assume we know more than we do’’–a theme I will
return to later. One respondent said that he would have refused
a request to write on the classification of the myositides, seeing
it as a forlorn task–I should have spoken to him earlier.
Why classify?
We will consider shortly the possible approaches to the classi-
fication of the myositides, but first need to consider why
classification is needed at all. Quite simply, the purpose of
classification is to delineate homogeneous groups within a
heterogeneous whole. But there may be a number of potential
defining characteristics and thus several possible, but very
different, classification systems for any particular disease
group. The classification system used will depend upon the
purpose for which the data is intended. Let us consider first
another, but familiar, disease area–muscular dystrophy.
Classification systems might include:
 by phenotype (e.g. Duchenne, Becker, limb-girdle, FSH,
oculopharyngeal, etc.);
 by ‘‘genotype’’ (e.g. dystrophinopathy, LGMD 1A-E, LGMD 2A-
L, etc.);
 by Mendelian pattern of inheritance (X-linked, autosomal
dominant or recessive);
 by the location of the affected protein (e.g. sarcolemmal,
myofibrillar, cytoplasmic).
For the molecular biologist, the last might be particularly
useful–aiding understanding of the fundamental disease me-
chanism and pointing towards possible therapeutic interven-
tions. But it is of little value to the clinician or patient. An
epidemiologist is likely to find the first category helpful, as it
gives sufficient detail of subgroups within the whole category
of the dystrophies. The clinician undoubtedly finds knowledge
of the Mendelian pattern of inheritance useful when discussing
counselling issues. The phenotypic pattern is a powerful clinical
pointer towards the diagnosis. But more specifically, subclas-
sification by genotype (knowing the specific gene/protein
involved) has proved to be extremely helpful not only in terms
of establishing diagnosis, but also indicating prognosis, and
alerting to the possibility of specific complications (e.g. cardi-
omyopathy and early ventilatory insufficiency in LGMD 2I).
For the myositides, we can distinguish between those condi-
tions for which we know the cause, and subclassify by aetiol-
ogy, and those for which we do not. But within both categories
the main aim is to be able to identify homogeneous groups of
patients. Some may be homogeneous because they have the
same aetiology, others homogeneous because they have si-
milar clinic-pathological characteristics, but however so defined
they should have similar characteristics in terms of natural
history/prognosis and response to treatment. It is unarguablytome 40 > n84 > avril 2011
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patient, andmust be at the heart of any system of classification.
The current difficulty is trying to identify a ‘‘gold standard’’
test/definition for each separate disease category.
On what basis to classify?
Most attempts at classification have been based on a combina-
tion of clinical and laboratory features, the latter including
muscle biopsy, electromyography, muscle enzymes and anti-
bodies. For some conditions either the aetiology is known (e.g.
infection, drug, toxin) or the inflammatory myopathy is seen in
association with a specific disease (e.g. sarcoidosis). For others
there is very strong evidence of an immune basis (e.g. DM and
PM). Sporadic IBM (sIBM) remains an enigma with features
suggesting both disturbed immunity and degeneration and,
rarely, genetic factors.
Weakness is a feature of most inflammatory myopathies, and is
typically proximal and axial in distribution, but not showing the
highly selective pattern of muscle involvement that is so
characteristic of many of the dystrophies. The exception, again,
is sIBM in which the early selective involvement of the forearm
flexors and quadriceps is virtually pathognomonic. Onset may
be subacute (e.g. DM, infection), measured in weeks, chronic
(e.g. PM), measured in months, or insidious and difficult to date
the onset (e.g. sIBM). With very rare exceptions, all are pro-
gressive without specific intervention.
The most specific associated clinical feature is rash in DM, with
cutaneous calcinosis sometimes being seen in childhood cases.
Interstitial lung disease, cardiac involvement and bowel infarc-
tion are potentially serious complications. Connective tissue
symptomatology includes Raynaud’s phenomenon, scleroder-
matous change, ‘‘mechanics’ hands’’, and arthropathy. DMmay
be a paraneoplastic disorder.
A final clinical feature that may aid classification is the response
to treatment. By and large the inflammatory myopathies
respond to steroids and other immunosuppressant drugs. Acute
DM usually responds well. In the more chronic myositides,
treatment may prevent further progression but recovery may
be limited by existing irreversible muscle damage. sIBM rarely
shows any substantial response to treatment, and indeed was
initially delineate in part because of its resistance to steroids
(‘‘treatment resistant PM’’). Sarcoid myopathy also often re-
sponds disappointingly to treatment.
Specific features on muscle biopsy have become paramount in
subclassifying the inflammatory myopathies. As noted, the
fundamental finding is the presence of inflammatory infiltrates.
However, the presence of such infiltrates is not in itself proof of
an inflammatory myopathy–by which we mean that an
inflammatory process is the primary cause of the myopathy.
A major confusing factor clinically is that similar infiltrates may
be seen in many dystrophies (i.e. genetically determined
disorders) and this not infrequently leads to erroneous diag-tome 40 > n84 > avril 2011nosis and treatment ([1] in this edition). This has been noted
particularly for dysferlinopathy, but is also seen in other dys-
trophies. It is possible that this presumed secondary inflam-
matory process may contribute to the clinical picture and trials
of steroids in dysferlinopathy are currently in progress. Experi-
ence to date suggests that the use of steroids to treat secondary
inflammation in the dystrophies is largely ineffective–and it is
very tempting to think that this may be analogous to what we
see in sIBM. Thus there is the school of thought that sIBM is
primarily a degenerative disorder and that the inflammatory
changes noted are only a secondary epiphenomenon, which
would explain the lack of response to immunosuppression
[2,3].
Study of the specific immunopathological changes in DM and
PM has led to the current concept that both are autoimmune
diseases but with very different effector mechanisms. Thus, DM
is a complement-dependent disorder in which immune attack
destroys capillaries leading to a form of ischaemic myopathy.
PM on the other hand is due to a MHC1-restricted, cytotoxic T-
cell-mediated destruction of muscle fibres [4]. As will be
discussed elsewhere, some argue that the immunopathological
subclassification of the inflammatory myopathies is more im-
portant than classification based on clinical and other patho-
logical criteria.
The presence of myositis-specific antibodies undoubtedly de-
fines certain subcategories of inflammatory myopathy. To date
their value has been restricted in part because of lack of general
availability, although that is changing and commercial diag-
nostic kits are now available. They lack sensitivity, being
present in somewhere between a third and one half of all
cases. There is no evidence that they are in themselves patho-
genic and in many instances may be unimportant epipheno-
mena, but nevertheless may prove to be useful diagnostically.
Many classifications have included electromyographic findings.
These include not only ‘‘myopathic’’ changes (small short
duration potentials), which are non-specific, but also the pre-
sence of ‘‘irritable’’ phenomena such as abnormal insertional
activity, positive sharp waves, fibrillation potentials and bizarre
high frequency discharges. The sensitivity and specificity of
such findings are limited.
With respect to ‘‘muscle enzymes’’, only the measurement of
serum creatine kinase (sCK) activity is indicated in clinical
practice. There is no longer any value in measuring other
enzymes, such as aldolase. It must be remembered that AST
and ALT are muscle as well as liver enzymes–that they are
measured so frequently in routine clinical practice means that
their increase may be the first pointer to a muscle disease, but
they have no advantage over sCK. sCK is often increased in the
inflammatorymyopathies, andmonitoring its fall in response to
treatment is undoubtedly helpful. But it is not invariably raised
in active disease, either before treatment is initiated, or during
relapse when on treatment.e2
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Box 1
Clinical classification (Walton and Adams)
1. Polymyositis
 Acute
 Subacute or chronic
2. Polymyositis and collagen disease
 Weakness the dominant feature + evidence of an associated
collagen disease
 Dermatomyositis
 Severe weakness with minimal or transient skin changes
3. Severe collagen disease with minor weakness (polymyositis)
 Dermatomyositis with florid skin changes and minor weakness
4. Polymyositis or dermatomyositis associated with malignancy
D Hilton-JonesIn summary, the nearest that we have to any form of gold
standard is the immunopathological study of muscle. However,
even that has limitations. To demand the demonstration of such
changes may hamper both routine clinical practice and re-
search. Specific changes may be absent simply due to the
vagaries of sampling. The same pathological changes may
be seen in very different clinical settings. Useful classification
systems thus depend upon a combination of clinical, patholo-
gical and other laboratory features.
Historical review of classification
As with many areas of myology, historical description of
myositis dates back two centuries, but what can be considered
the modern era started only in the 1950s–a period when
clinicians first made rigorous attempts to classify the different
forms of muscle disease and new muscle biopsy staining
techniques were being developed. Eaton reported on 41 cases,
including clinical, neurophysiological and pathological findings
[5]. His cases included many with DM or scleroderma. Walton
and Adams published a monograph (‘‘Polymyositis’’) in which
they reviewed the literature and reported detailed clinical and
laboratory findings in 40 patients [6]. As was to be the case for
another 30 years they considered DM and PM to be essentially
the same, differentiated only by the presence or absence of a
rash. Even without a rash they noted that PM could be acute,
but also that chronic PMwas difficult to distinguish clinically and
sometimes pathologically from the dystrophies. The relation-
ship with neoplasia was ‘‘sufficiently clear to indicate that a
careful search should be made for malignancy in any patient
suffering from DM or PM’’. They also noted the close relation-
ship with collagen disease–‘‘Sometimes the symptoms and
signs of muscle disease are predominant, but in other cases
they are obscured by skin changes or the manifestations of an
associated collagen disease. Even when the muscle weakness
is predominant there may be features such as the Raynaud
phenomenon, localised scleroderma of the hands or rheuma-
toid arthritis. . .’’. Their clinical classification is given in Box 1. As
will be seen, it is remarkable how similar this looks to all future
attempts at reclassification.
Walton and Adams also made some prescient pathological
observations. In the more modern terminology of lumping
versus splitting they noted ‘‘The basic uniformity of the histo-
logical change, in conformity with the nosology of the clinical
disease, leads us to conclude, for the moment, that all such
cases should be considered as a single syndrome’’. They noted
the occasional absence of cellular infiltrates and whilst accept-
ing that this might be due to inaccurate sampling also sug-
gested that it ‘‘might imply an aetiology other than allergy’’.
These cases may have represented what we now call necrotiz-
ing myopathy, and which may be either metabolic or immune-
mediated in origin. Their cases with vacuolar change were
almost certainly examples of sIBM.It was then nearly 20 years before the next major review of
classification and the papers of Bohan and Peter [7–9]. There is
no doubting their importance and they have acted as a frame-
work for diagnosis and epidemiological studies ever since.
Arguably, over-strict adherence to them has to some extent
stifled debate and it is appropriate to remember that in the first
of their papers they stressed that their criteria were ‘‘empiri-
cally derived’’ and that failure to meet the criteria did not
necessarily exclude the diagnosis of PM and DM. Although it can
hardly be called a failing, given knowledge available at the
time, a ‘‘criticism’’ of their criteria is that they fail to recognise
sIBM as a specific entity. Bohan and Peter recognised the need
for accurate classification and looked to develop diagnostic
criteria akin to those used for rheumatic fever and rheumatoid
arthritis. They proposed five major diagnostic criteria to define
DM and PM (Box 2).
The diagnosis of DM or PM could be considered Definite,
Probable or Possible depending upon the number of criteria
met, with cutaneous features being a sine qua non of DM
(Box 3).
With respect to overall classification of the IIM they proposed
five groups, with each of which could be further defined as
definite, probable or possible according to the above diagnostic
criteria:
 I: primary, idiopathic PM;
 II: primary, idiopathic DM;
 III: DM or PM associated with neoplasia;
 IV: childhood DM (or PM) associated with vasculitis;
 V: DM or PM with associated collagen-vascular disease.
Many would argue that the Bohan and Peter approach to
classification and establishment of diagnostic criteria has
served us well for many years, but it is clear that, as they said,
their approach was empirical, based on observation. Perforcetome 40 > n84 > avril 2011
Box 2
Five major diagnostic criteria to define DM and PM (Bohan and
Peter)
I. Weakness
 Symmetrical
 Limb-girdle distribution
 Involving anterior neck flexors
 Progressive over weeks to months
 There may be dysphagia
 There may be ventilatory muscle involvement
II. Muscle biopsy evidence of:
 Necrosis of type 1 and 2 fibres
 Phagocytosis
 Regeneration
 Perifascicular atrophy
 Inflammatory exudate
III. Elevated muscle enzymes in serum
IV. Electrophysiological triad
 Small, short, polyphasic units
 Fibrillations, positive sharp waves, insertional instability
 Bizarre high-frequency repetitive discharges
V. Dermatological features
 Heliotrope discolouration of eyelids + periorbital oedema
 Scaly, erythematous dermatitis (Gottron’s sign)
Box 3
Diagnosis of DM or PM: ‘‘Definite’’, ‘‘Probable’’ or ‘‘Possible’’
(Bohan and Peter)
 Definite
 DM: 3 or 4 major criteria (+ rash)
 PM: 4 criteria (no rash)
 Probable
 DM: 2 major criteria (+ rash)
 PM: 3 major criteria (no rash)
 Possible
 DM: 1 major criterion (+ rash)
 PM: 2 major criteria (no rash)
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pathogenetic mechanisms. They noted that there were excep-
tions, and also that diagnosis depended upon exclusion of all
other myopathies that might mimic the IIM–in itself a challen-
ging task. Future research would show fundamental differences
in the immunopathogenic mechanisms in DM and PM, that the
muscle pathology of DM could be seen in patients without atome 40 > n84 > avril 2011rash, and that almost certainly many patients diagnosed as
having PM on Bohan and Peter criteria actually had sIBM.
At this point in the chronology it is appropriate to comment
upon the emergence of sIBM and development of its diagnostic
criteria. From its first recognition as a separate disorder in the
late 1960s [10] we now realise that sIBM is the most prevalent
of the IIM (ignoring for the moment the question of whether it
is truly a primary inflammatory myopathy). As with the seminal
papers of Bohan and Peter for DM and PM, a single paper stands
out concerning diagnostic criteria for sIBM [11]. And as with
Bohan and Peter, rigid adherence to these initial criteria may to
some extent have clouded further thought. A slightly unusual
feature of the Griggs’ criteria is that a diagnosis of definite sIBM
can bemade on histological grounds alone, without the need to
fulfill any clinical criteria. In practice, there is little evidence that
this approach might lead to erroneous diagnosis–that is, the
pathological criteria as defined appear to be 100% specific for
sIBM. The problem, some have argued, is that there are many
patients who indubitably have sIBM who do not, at the time of
their first diagnostic biopsy, show the canonical pathological
features insisted upon by Griggs [12–14]. The evidence that
they ‘‘indubitably have sIBM’’ is three-fold. Firstly, they have
the highly distinctive, some would say essentially pathogno-
monic, clinical features of sIBM in terms of distribution of
weakness, and follow the typical natural history of the condi-
tion in terms of rate of progression. Secondly, if a second biopsy
is taken from another muscle shortly after the first biopsy, the
canonical features may be seen. Thirdly, if the biopsy is
repeated some time later then again the characteristic features
may be seen. These latter two observations suggest two
possibilities. Firstly, as is seen in DM, the pathological changes
throughout the body may be patchy–whether the characteristic
changes are seen is something of a lottery. The second, and
more concerning possibility, is that the canonical pathological
features may represent a late stage of the disease, and are
indeed absent early on. sIBM is recognised as being highly
resistant to immunomodulatory therapies (an argument
against it being primarily an immune-mediated disorder) but
maybe such treatments initiated at an earlier stage in the
disease process would be more successful. On the basis of
these arguments, revised criteria have been proposed that
place greater emphasis on the clinical features–the pathological
features still have to be consistent with the diagnosis, but the
previously considered essential pathological changes need not
be present [12,13].
Returning to DM, PM and allied IIM, insight into pathogenic
mechanisms (but not into specific aetiologies) came from the
outstanding immunopathological studies of Arahata and Engel
in the 1980s [15–20]. In very brief summary, their detailed
analysis of mononuclear cell subsets and related phenomena
indicated that despite all of the clinical and superficial
pathological similarities, PM and DM have fundamentallye2
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e2
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D Hilton-Jonesdifferent efferent immune mechanisms (but as noted no
clues as to the afferent process–i.e. what triggers these
events). DM is due to complement-mediated mechanisms
that lead to loss of intramuscular capillaries, and is thus a
form of microangiopathy. PM on the other hand is related to
T-cell-mediated cytotoxicity. It would be incorrect to say that
all of the immunopathological observations have been fully
explained. For example, it is not clear why in DM there is
widespread up-regulation of MHC-1 expression. In PM such
expression is a pre-requisite to T-cell-mediated cytotoxicity,
but that does not occur in DM. In everyday clinical practice it
is not always easy to firmly classify the biopsy findings as PM
or DM, and clinical correlation is vital. As discussed earlier,
this may simply reflect the vagaries of sampling. On the other
hand, the not infrequent lack of specific pathological changes
has led some to conclude that PM is an overdiagnosed entity
(see below) [21].
A review in 2003 summarised developments in the field and
emphasised the central importance of the immunopathological
findings [4]. This viewpoint was challenged with the sugges-
tions that immunopathological testing was not widely avail-
able, that muscle biopsy had low sensitivity, and that there was
no evidence of the performance characteristics of the proposed
new diagnostic criteria [22]–implicit in the latter was that the
long-used Bohan and Peter criteria were ‘‘clinically practical,
sensitive, specific’’, and that any new criteria should be com-
pared to those and be ‘‘derived from well-designed, prospec-
tive, comprehensive studies’’. It was an obvious irony that the
Bohan and Peter criteria had themselves not been derived in
such a fashion. Dalakas and Hohfeld responded that of course
the biopsy immunopathological techniques are relatively sim-
ple and widely available, and that the Bohan and Peter criteria
had been a ‘‘source of constant error’’. Elements of the dispute
linger, possibly in part because rheumatologists, immunologists
and myologists are seeing somewhat different populations of
patients.
A quite different approach to classification relates to the
identification of so-called myositis-specific antibodies (MSA),
and here again the views of specialists from different disci-
plines vary, possibly because the type of patient seen within
each discipline varies. Many antibodies are found in association
with inflammatory myopathies (e.g. anti-nuclear antibody,
anti-PM/Scl) but are not specific to these diseases. By defini-
tion, the MSAs are only seen, with rare exceptions, in patients
with myositis, and most patients with MSAs have myositis [23–
30]. It is very rare for any one patient to have more than one
MSA. Certain MSAs are also associated with specific HLA hap-
lotypes. Broadly speaking MSAs fall into one of three groups:
anti-tRNA synthetases, anti-signal recognition particle (SRP)
and anti-Mi-2.
Anti-tRNA synthetase antibodies include anti-Jo1–this has long
been associated with the presence of interstitial lung disease(ILD), but not all patients with anti-Jo1 have ILD, patients with
ILD may not have anti-Jo1, and patients with anti-Jo1 may have
ILD or arthritis without myositis. The anti-synthetase syndrome
is relatively well-defined but the aetiology is unknown and it is
not clear that the detected antibodies are pathogenic–the
characteristic clinical features include myositis, which tends
to be severe, ILD, mechanic’s hands (hardening and dirty-
looking cracking of the skin), non-erosive arthritis in the hands,
and Raynaud’s phenomenon. Rash is usually absent.
Anti-SRP antibodies were initially particularly associated with a
rapidly progressive severe myopathy that was resistant to
steroids. Later studies indicated that biopsy often showed
features of a necrotising myopathy without inflammatory
exudates [31]. Furthermore, the clinical picture is clearly more
diverse, with slowly progressive cases mimicking limb-girdle
dystrophy [32,33], and many cases respond satisfactorily to
treatment.
Anti-Mi2 antibodies are associated with DM–the rash often
being florid and the response to treatment good.
Love looked at 212 patients including 58 with PM, 79 with DM,
26with sIBM, 36with connective-tissue disease (CTD)/myositis
overlap, and 13 with cancer diagnosed within one year of the
myositis [26]. They identified MSAs in 66/212. Those with anti-
synthetase antibodies more frequently had arthritis, fever, ILD
and mechanic’s hands, needed a higher mean dose of steroids,
where more likely to require the addition of a cytotoxic drug,
and had a higher mortality rate. Seven with anti-SRP antibodies
had acute onset, severe weakness and resistance to treatment.
Two with anti-Mi2 antibodies had acute onset, marked DM
cutaneous features and a good response to treatment.
Targoff et al. proposed revising the diagnostic criteria for the IIM
to include MSA screening [24]. They suggested that this would
allow definite PM to be diagnosedwithout amuscle biopsy, and
definite DM without EMG and muscle biopsy. The limited
sensitivity (no more than one half of patients with IIM have
any of the MSAs) and currently rather limited evidence of
specificity, at least in terms of a specific clinical syndrome,
limit this approach and at best such investigations should be
considered ancillary, although it will certainly be of interest to
see if there is a useful correlation between the presence of a
specific MSA and the response to treatment and overall prog-
nosis.
In 2003 van der Meulen and colleagues published a paper
suggesting that PM is an overdiagnosed entity [21]. On the
basis of the immunopathological findings discussed above,
suggesting a clear distinction between DM and PM, van der
Meulen required the presence of endomysial mononuclear cells
surrounding, and preferably invading, non-necrotic fibres to
make a diagnosis of definite PM. If the inflammatory infiltrate
was not endomysial, but perimysial/perivascular, they classi-
fied the patient as having ‘‘unspecified myositis’’. They also
excluded the diagnosis of PM if there was an associatedtome 40 > n84 > avril 2011
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not that PM was overdiagnosed, but that the authors were
guilty of over-adherence to unvalidated pathological diagnostic
criteria [34]. As already noted, it is certainly not uncommon in
everyday practice to see biopsies lacking specific changes. The
biopsy appearance has to be interpreted along with the clinical
picture and other laboratory findings and it is not surprising that
not every laboratory abnormality will be present in every case.
In most instants it is possible to categorise the patient as having
DM, PM or myositis associated with a CTD, and in the latter
group it may be semantic as to whether to call it myositis or PM.
A major reason for attempting classification is to ensure homo-
geneous groups for clinical trials. With trial design in mind a
European Neuromuscular Centre Workshop in 2003 proposed
revised diagnostic criteria and overall classification which drew
upon the developments, described above, since the 1975
Bohan and Peter classification [35].
Five major groups representing the IIM were proposed:
 1: inclusion-body myositis;
 2: PM;
 3: DM;
 4: non-specific myositis;
 5: immune-mediated necrotising myopathy.
PM and DM could be further categorised as definite or prob-
able, depending on the presence of specific clinical and la-
boratory criteria. Subcategories of DM included DM sine
dermatitis and amyopathic DM–the former on the basis of
the characteristic immunopathological muscle biopsy findings
of DM, but in the absence of a rash, and the latter with a typical
rash and skin biopsy showing appropriate immunopathologi-
cal findings, but no clinical or pathological evidence of muscle
involvement. As discussed above, non-specific myositis de-
pends upon the presence of inflammatory cells, but not sur-
rounding and invading non-necrotic fibres. Immune-mediated
necrotising myopathies behave clinically like other myositides
in terms of pattern of muscle involvement, progression and
response to immunosuppression, and the biopsy shows ne-
crotic fibres but in the absence of inflammatory infiltrates.
Groups 2, 3, 4 and 5 may each be associated with features of
connective tissue disease, and each group may also be asso-
ciated with neoplasia.
Two very recent reviews have looked at the issues and
difficulties surrounding diagnostic criteria and classification,
but added no new observations [36,37]. The need for further
international collaboration between interested specialists
was emphasised and the goals of the International
Myositis Assessment and Clinical Studies (IMACS) group
noted [37].
Conclusion
I am told that in the 1970s the rheumatologists at a large
London teaching hospital were wont to use the abbreviationtome 40 > n84 > avril 2011SSOM–some sort of myositis. I assume that this was an honest
attempt to indicate ignorance about cause and that they felt
more comfortable ‘‘lumping’’ cases with many common fea-
tures together, rather than ‘‘splitting’’ up into subcategories
when there was no clear rationale to do so. Are we now any the
wiser? I think that the answer is definitely yes, but note again
the wise words of my colleague who warned against rigid
definitions in that they may lead us to assume we know more
than we do. The major development relates to our increased
understanding of the immunopathogenesis of DM and PM,
although it is clear that we do not understand all of the relevant
mechanisms.
It is salutary to remember why we are trying to achieve a
system of classification, and how we might go about doing so.
The critical relationship between establishing diagnostic criteria
and any system of classification has been emphasised. The
main benefits of classification are in aiding the diagnostic
approach, defining specific subgroups that have a similar
natural history and response to treatment, and leading on from
that are helpful for epidemiological studies. Arguably, definitive
classification depends upon identifying the specific cause of
each disorder. A comparison can be made with limb-girdle
muscular dystrophy. In the 1950s we were able to define LGMD
by clinical features and certain histological features. We could
see that some patients had particular associated features
whereas others did not–e.g. cardiomyopathy or early ventila-
tory muscle involvement. Now we can define individual sub-
types at a molecular level and note which are associated with
such complications. For the myositides we are somewhere
between these two stages.
Box 4 is essentially a synthesis of previous classifications that is
intended to be useful clinically–in other words, most patients
can, on the basis of clinical and laboratory features, be placed in
a specific category. The first part of Box 4 lists conditions with
either a known cause (rather few) or those in which myositis is
associated with another definable entity, although the patho-
genic relationship between the two may be uncertain. The
second part includes what are frequently referred to as the IIM.
Specific myositides
Infections directly affecting muscle are rare in the Western
world. Similarly eosinophilia-myalgia syndrome, toxic oil syn-
drome and macrophagic myofasciitis are very rare, and the
latter essentially confined to France. There is increasing evi-
dence that statins may induce an immune-mediated necrotis-
ingmyopathy which persists on statin withdrawal and responds
to immunosuppressant drug therapy [38,39]. It is of note that
statins can also induce potentially fatal rhabdomyolysis through
presumed metabolic dysfunction–the condition is self-limiting
but in the immediate aftermath the appearance of a necrotising
myopathy may be very similar to the immune-mediated dis-
order.e2
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Box 4
A clinically useful classification of the myositides
(1) Specific aetiology or clinic-pathological association
Infections
 Viral, bacterial, parasitic
Toxic syndromes
 Eosinophilia-myalgia syndrome (tryptophan)
 Toxic oil syndrome (? toxin)
 Macrophagic myofasciitis (aluminium)
 Drug-induced (e.g. statins)
Sarcoidosis
Vasculitides
Specific connective-tissue disorder
 Rheumatoid arthritis
 SLE
 Sjögren’s syndrome
 Scleroderma
 Mixed connective tissue disease
 Anti-synthetase syndrome
(2) Idiopathic
Immune-mediated
 Dermatomyositis ( CTD,  CA)*
 Polymyositis ( CTD)
 Non-specific myositis ( CTD)
 Necrotising myopathy ( CA)
Uncertain pathological mechanisms
 Sporadic inclusion-body myositis
*CTD: connective-tissue disease; CA: cancer.
D Hilton-JonesGranulomata in muscle are sometimes sought in order to
confirm a diagnosis of sarcoidosis, but clinically significant
muscle disease is rare. A clinical pattern similar to sIBM, with
distal weakness affecting the finger flexors, has been described
[40]. Response to immunosuppressant therapy is often poor. As
with sarcoidosis, many vasculitides may produce changes in
muscle that can aid diagnosis, but clinically significant muscle
involvement is rare.
The frequent coexistence of myositis with symptoms and signs
of CTD is striking. Previous authors have distinguished, in
arguably somewhat arbitrary fashion, between associated
and overlapping conditions [41]. For the purposes of this
classification I have considered two scenarios. Firstly, the
occurrence of myositis with a clearly defined CTD–the CTD
should fulfill its own diagnostic criteria. Rarely PM may be seen
in association with rheumatoid arthritis. Muscle involvement
may also be secondary to neuropathy and vasculitis. Equallyrarely, SLE and Sjögren’s syndrome can be associated with
either DM or PM. Myositis is somewhat more common in
association with scleroderma and mixed connective-tissue
disease (MCTD), and is often of the ‘‘non-specific’’ type. The
anti-PM/Scl antibody may be seen in patients with scleroder-
ma-myositis, but also in patients with isolatedmyositis. MCTD is
a somewhat contentious entity–clinical features in addition to
myositis include swollen hands (with acrosclerosis), Raynaud’s
phenomenon, pulmonary involvement, and the presence of the
extractable nuclear antigen U1 snRNP. The anti-synthetase
syndrome was described earlier.
Idiopathic
The immune-mediated disorders include DM and PM defined by
the clinical and immunopathological features discussed earlier.
In particular, PM requires the specific finding of endomysial
inflammatory infiltrates surrounding, and preferably invading,
non-necrotic muscle fibres which are expressing MHC-1. In both
categories, patients may have features of a CTD but not with
enough features to allow the diagnosis of a specific condition.
Clinical features may include Raynaud’s phenomenon, arthral-
gia, and arthritis, and serological markers anti-nuclear antibo-
dies, rheumatoid factor, anti-PM/Scl, and others.
The debate as to whether PM is overdiagnosed, or that insisting
on the specific features of the endomysial infiltrates is inap-
propriate and reduces diagnostic sensitivity, is accommodated
by inclusion of a category of non-specific myositis. This may
seem to be an ‘‘opt-out’’ but the truth is we do not know
whether or not the particular pattern of inflammatory infiltrate
is crucial. Until aetiology is determined this dilemma will
remain and it is better to acknowledge it rather than trying
to force a classification without evidence. It certainly does not
mean, as has been suggested rather provocatively, that this will
‘‘leave many myositis patients diagnostically adrift and ex-
cluded from receiving potentially effective treatment’’ [34].
Rather, clinical trials should simply subcategorise patients
according to the pathological findings. Furthermore, this cate-
gory also helps us accommodate those patients in whom the
clinical picture is typical of myositis, they respond to immuno-
suppressant therapy, but the muscle biopsy studies simply do
not allow certain classification on current criteria. As with PM
and DM there may be associated features of CTD.
It seems likely that idiopathic immune-mediated necrotising
myopathy will prove to be aetiologically diverse. It may cer-
tainly be seen as a paraneoplastic condition, and is also
associated with the presence of anti-SRP antibodies.
For over 30 years most authors have considered sIBM to be one
of the IIM. There is no doubt that the immunopathological
findings are very similar to those seen in PM. But determined
attempts at immunosuppression have proved ineffective. In
addition there is abundant evidence of ‘‘degenerative’’ pro-
cesses involving nuclei [2]. Is the degenerative pathologytome 40 > n84 > avril 2011
Observations on the classification of the inflammatory myopathies
MYOSITISprimary and the inflammation secondary? We simply do not
know and for the time being I think it is reasonable to move
sIBM a little away from PM and DM, hence its separate
classification.
If Box 4 is compared with Walton and Adams’ 1958 classifica-
tion [6], one might be somewhat despondent about the pro-
gress that has been made in the intervening half-century, but
that would be unduly pessimistic. We have a very much clearer
insight into immunopathogentic mechanisms, but still havetome 40 > n84 > avril 2011much to learn about the afferent limb of the immune process.
There have been interesting and diagnostically valuable ob-
servations concerning MSAs. The more we have learnt, the
more we have appreciated that it is rare for any single test to
provide all of the answers, and that the diagnostic process, as
well as any attempts at classification, relies on combining
clinical observation with appropriate laboratory tests.Conflicts of interests: noneReferences
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